---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-118569"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:35:20.523612+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexeo announces positive interim Phase 1/2 data for LX1001 gene therapy in APOE4 Alzheimer's

## Summary
- LX1001 showed dose-dependent APOE2 expression in all participants with durability to 12 months.
- CSF tau biomarkers (T-tau, P-tau181, P-tau217, P-tau231) reduced in >2/3 of participants relative to baseline.
- No reports of ARIA; four SAEs reported, one hearing loss possibly related, repeat audiometry pending.
- Company initiated FDA engagement; expects update on regulatory interactions and development plans in 2025.

## SEC filing metadata
- accession: 0000950170-24-118569
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017024118569/0000950170-24-118569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017024118569/lxeo-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-118569
- JSON: https://secwatch.observer/filing/0000950170-24-118569.json
- Plain text: https://secwatch.observer/filing/0000950170-24-118569.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.